{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T16:17:11Z","timestamp":1788797831554,"version":"build-2803163510"},"reference-count":46,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T00:00:00Z","timestamp":1559174400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2019,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>While doses of deferiprone up to 75\u00a0mg\/kg\/d have been demonstrated to be effective in cardiac iron removal, their efficacy in the reduction of liver iron has been equivocal. The aim of this study was to evaluate the effect of deferiprone dose on liver iron concentrations in adult iron overload patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A single\u2010centered, retrospective, cohort observational study was conducted involving 71 patients exposed to deferiprone doses up to 113\u00a0mg\/kg\/d between January 2009 and June 2015 for a median of 33\u00a0months.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>At the end of the study period, liver iron measured by R2 MRI was reduced by a mean 1.7\u00a0mg\/g dw. A dose effect was observed, with incremental reductions of 2.8\u00a0mg\/g dw in end of study LIC for every 10\u00a0mg\/kg\/d higher dose of deferiprone (<jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.001). A dose effect was also observed in end of study ferritin and cardiac iron concentration measured by T2* MRI (<jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.0001 and <jats:italic>P<\/jats:italic>\u00a0=\u00a00.048, respectively). No associations between adverse effects and deferiprone dose were observed, but there was a trend toward higher rates of agranulocytosis at higher doses and two of three hereditary hemochromatosis patients developed this complication.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The present study failed to demonstrate that the use of deferiprone at &gt;90\u00a0mg\/kg\/d was associated with increased risk of agranulocytosis or neutropenia, but did demonstrate more effective liver iron control in iron overload patients.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ejh.13244","type":"journal-article","created":{"date-parts":[[2019,5,8]],"date-time":"2019-05-08T15:00:02Z","timestamp":1557327602000},"page":"80-87","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Deferiprone exerts a dose\u2010dependent reduction of liver iron in adults with iron overload"],"prefix":"10.1111","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6596-9328","authenticated-orcid":false,"given":"Andrew","family":"Binding","sequence":"first","affiliation":[{"name":"Division of Hematology University of Toronto Toronto Ontario Canada"},{"name":"Divison of Medical Oncology &amp; Hematology University Health Network Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4807-8603","authenticated-orcid":false,"given":"Richard","family":"Ward","sequence":"additional","affiliation":[{"name":"Division of Hematology University of Toronto Toronto Ontario Canada"},{"name":"Divison of Medical Oncology &amp; Hematology University Health Network Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Tomlinson","sequence":"additional","affiliation":[{"name":"Institute of Health Policy, Management, and Evaluation University of Toronto Toronto Ontario Canada"},{"name":"Department of Public Health Sciences University of Toronto Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6744-9238","authenticated-orcid":false,"given":"Kevin H. M.","family":"Kuo","sequence":"additional","affiliation":[{"name":"Division of Hematology University of Toronto Toronto Ontario Canada"},{"name":"Divison of Medical Oncology &amp; Hematology University Health Network Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,5,30]]},"reference":[{"issue":"10","key":"e_1_2_7_2_1","first-page":"1187","article-title":"Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine","volume":"89","author":"Borgna\u2010Pignatti C","year":"2004","journal-title":"Haematologica"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.2471\/BLT.06.036673"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07970.x"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1186\/1532-429X-13-45"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2011.06.065"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1053\/euhj.2001.2822"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.05104.x"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1990.tb07887.x"},{"key":"e_1_2_7_10_1","unstructured":"ApoPharma. Ferriprox (deferiprone) product monograph. In: Canada H ed2015."},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)09740-4"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0082662"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07609.x"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199504063321404"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.648790"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/03630260600642617"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1006\/bcmd.2002.0510"},{"issue":"10","key":"e_1_2_7_18_1","first-page":"264a","article-title":"Final results of the randomized trial of deferiprone (L1) and deferoxamine (DFO) (abstract 1161)","volume":"90","author":"Olivieri NF","year":"1997","journal-title":"Blood"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-07-2948"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.3109\/03630269.2014.965781"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.11414"},{"issue":"9","key":"e_1_2_7_22_1","first-page":"1241","article-title":"A prospective randomized controlled trial on the safety and efficacy of alternating deferoxamine and deferiprone in the treatment of iron overload in patients with thalassemia","volume":"91","author":"Galanello R","year":"2006","journal-title":"Haematologica"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.110.007641"},{"issue":"1","key":"e_1_2_7_24_1","first-page":"21","article-title":"Comparative efficacy of desferrioxamine, deferiprone and in combination on iron chelation in thalassemic children","volume":"41","author":"Gomber S","year":"2004","journal-title":"Indian Pediatr"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12517"},{"issue":"8","key":"e_1_2_7_26_1","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1182\/blood.V83.8.2329.2329","article-title":"Iron\u2010balance and dose\u2010response studies of the oral iron chelator 1,2\u2010dimethyl\u20103\u2010hydroxypyrid\u20104\u2010one (L1) in iron\u2010loaded patients with sickle cell disease","volume":"83","author":"Collins AF","year":"1994","journal-title":"Blood"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23386"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2011.07.002"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-01-0177"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2002.03554.x"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-10-3280"},{"key":"e_1_2_7_32_1","unstructured":"FDA. Ferriprox (deferiprone) product monograph. In: Administration FaD ed2011."},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24479"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.18637\/jss.v032.i03"},{"key":"e_1_2_7_35_1","volume-title":"A Language and Environment for Statistical Computing","author":"R Core Team","year":"2016"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1177\/000456328702400510"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1017\/S148180350001054X"},{"key":"e_1_2_7_38_1","volume-title":"Guidelines for the Management of Transfusion Dependent Thalassaemia (TDT)","author":"Cappellini MD","year":"2014"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1186\/1532-429X-15-38"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21993"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-014-0671-2"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.3109\/03630269.2011.570674"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1080\/10245330701521614"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04240.x"},{"issue":"6","key":"e_1_2_7_45_1","first-page":"655","article-title":"Comparison between deferoxamine and combined therapy with deferoxamine and deferiprone in iron overloaded thalassemia patients","volume":"12","author":"Tamaddoni A","year":"2010","journal-title":"Iran Red Crescent Med J"},{"key":"e_1_2_7_46_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23219"},{"key":"e_1_2_7_47_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24024"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fejh.13244","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.13244","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ejh.13244","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.13244","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,9]],"date-time":"2023-09-09T17:49:17Z","timestamp":1694281757000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.13244"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,30]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["10.1111\/ejh.13244"],"URL":"https:\/\/doi.org\/10.1111\/ejh.13244","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,30]]},"assertion":[{"value":"2019-02-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-04-30","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-05-30","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}